MedTrace Logo

A Phase 2 Study of IC14 in Acute Respiratory Distress Syndrome

NCT03017547 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2026-05-05

No results posted yet for this study

Summary

Acute Respiratory Distress Syndrome (ARDS) patients will be randomized to receive either IC14 (a single dose of 4 mg/kg followed by 2 mg/kg on Days 2-4) or placebo. Study participation will be for a total of 28 days.

Conditions

  • Acute Respiratory Distress Syndrome

Interventions

DRUG

IC14

Blocks CD14 signalling which is responsible for disease pathogenesis in ARDS

OTHER

Placebo

sterile normal saline for infusion

Sponsors & Collaborators

  • Implicit Bioscience

    lead INDUSTRY

Principal Investigators

  • Jan Agosti, MD · Implicit Bioscience

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-30
Primary Completion
2020-06-30
Completion
2020-06-30
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03017547 on ClinicalTrials.gov